Literature DB >> 26518771

Higher incidence of the SNP Met 788 Ile in the coding region of A20 in diffuse large B cell lymphomas.

Kerstin Wenzl1, Sybille Hofer1, Katharina Troppan1, Markus Lassnig1, Elisabeth Steinbauer2, Marco Wiltgen3, Barbara Zulus4, Wilfried Renner4, Christine Beham-Schmid2, Peter Neumeister1, Alexander Deutsch5.   

Abstract

Genetic alterations causing constitutive activation of the nuclear factor kappa B (NF-κB) signaling pathway has been associated with the development of lymphomas. A20 (TNFAIP3) is a key regulator of NF-κB signaling. Its suppressor functions are often inactivated by deletions and/or mutations in various hematologic malignancies. Since we recently found the rs143002189 polymorphism in the A20 loci in our multiple myeloma samples, we further investigated this polymorphism in different lymphoid neoplasias. For this purpose, we tested 479 cases of the most common B cell malignancies for the presence of the rs143002189 polymorphism. We found a significant higher occurrence of the rs143002189 polymorphism in diffuse large B cell lymphoma (DLBCL) compared to non-neoplastic controls and other types of B cell malignancies. Furthermore, structure analyses of the mutated A20 protein led to the assumption that the new steric interaction within the protein is responsible for a reduced or inactivated A20 protein. Our data indicates that in a significant fraction of patients, rs143002189 might contribute to the development of DLBCL.

Entities:  

Keywords:  A20; DLBCL; Lymphoma; Polymorphism

Mesh:

Substances:

Year:  2015        PMID: 26518771     DOI: 10.1007/s13277-015-4322-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  20 in total

1.  Protein Data Bank (PDB): database of three-dimensional structural information of biological macromolecules.

Authors:  J L Sussman; D Lin; J Jiang; N O Manning; J Prilusky; O Ritter; E E Abola
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1998-11-01

2.  Characterization of 6q deletions in mature B cell lymphomas and childhood acute lymphoblastic leukemia.

Authors:  Emma Flordal Thelander; Koichi Ichimura; Martin Corcoran; Gisela Barbany; Ann Nordgren; Mats Heyman; Mattias Berglund; Andy Mungall; Richard Rosenquist; V Peter Collins; Dan Grandér; Catharina Larsson; Svetlana Lagercrantz
Journal:  Leuk Lymphoma       Date:  2008-03

Review 3.  A20: from ubiquitin editing to tumour suppression.

Authors:  Sarah G Hymowitz; Ingrid E Wertz
Journal:  Nat Rev Cancer       Date:  2010-04-12       Impact factor: 60.716

4.  Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.

Authors:  Laurie H Sehn; Jane Donaldson; Mukesh Chhanabhai; Catherine Fitzgerald; Karamjit Gill; Richard Klasa; Nicol MacPherson; Susan O'Reilly; John J Spinelli; Judy Sutherland; Kenneth S Wilson; Randy D Gascoyne; Joseph M Connors
Journal:  J Clin Oncol       Date:  2005-06-13       Impact factor: 44.544

5.  Distinct signatures of B-cell homeostatic and activation-dependent chemokine receptors in the development and progression of extragastric MALT lymphomas.

Authors:  A J A Deutsch; A Aigelsreiter; E Steinbauer; M Frühwirth; H Kerl; C Beham-Schmid; H Schaider; P Neumeister
Journal:  J Pathol       Date:  2008-08       Impact factor: 7.996

6.  TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas.

Authors:  Keiichiro Honma; Shinobu Tsuzuki; Masao Nakagawa; Hiroyuki Tagawa; Shigeo Nakamura; Yasuo Morishima; Masao Seto
Journal:  Blood       Date:  2009-07-16       Impact factor: 22.113

7.  Genome-wide array-based comparative genomic hybridization of ocular marginal zone B cell lymphoma: comparison with pulmonary and nodal marginal zone B cell lymphoma.

Authors:  Won Seog Kim; Keiichiro Honma; Sivasundaram Karnan; Hiroyuki Tagawa; Yoon Duck Kim; Young Lyun Oh; Masao Seto; Young Hyeh Ko
Journal:  Genes Chromosomes Cancer       Date:  2007-08       Impact factor: 5.006

8.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

9.  Frequent inactivation of A20 in B-cell lymphomas.

Authors:  Motohiro Kato; Masashi Sanada; Itaru Kato; Yasuharu Sato; Junko Takita; Kengo Takeuchi; Akira Niwa; Yuyan Chen; Kumi Nakazaki; Junko Nomoto; Yoshitaka Asakura; Satsuki Muto; Azusa Tamura; Mitsuru Iio; Yoshiki Akatsuka; Yasuhide Hayashi; Hiraku Mori; Takashi Igarashi; Mineo Kurokawa; Shigeru Chiba; Shigeo Mori; Yuichi Ishikawa; Koji Okamoto; Kensei Tobinai; Hitoshi Nakagama; Tatsutoshi Nakahata; Tadashi Yoshino; Yukio Kobayashi; Seishi Ogawa
Journal:  Nature       Date:  2009-05-03       Impact factor: 49.962

10.  Frequent down regulation of the tumor suppressor gene a20 in multiple myeloma.

Authors:  Katharina Troppan; Sybille Hofer; Kerstin Wenzl; Markus Lassnig; Beata Pursche; Elisabeth Steinbauer; Marco Wiltgen; Barbara Zulus; Wilfried Renner; Christine Beham-Schmid; Alexander Deutsch; Peter Neumeister
Journal:  PLoS One       Date:  2015-04-09       Impact factor: 3.240

View more
  2 in total

1.  Genetic polymorphism and transcriptional regulation of CREBBP gene in patient with diffuse large B-cell lymphoma.

Authors:  Haifeng Zhao; Yutian Kan; Xinyuan Wang; Leiyuan Chen; Peng Ge; Zhengzi Qian
Journal:  Biosci Rep       Date:  2019-08-13       Impact factor: 3.840

2.  Comprehensive analysis of the expression and prognosis for TNFAIPs in head and neck cancer.

Authors:  Gaochen Lan; Xiaoling Yu; Xin Sun; Wan Li; Yanna Zhao; Jinjian Lan; Xiaolong Wu; Ruilan Gao
Journal:  Sci Rep       Date:  2021-08-03       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.